Hypothesis: This study determined the parameters for predicting the clinical effects of eplerenone (Ep) add-on therapy on blood pressure (BP) and proteinuria in patients taking angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II type I receptor blockers (ARBs). Materials and methods: Patients were treated with a gradual increase of Ep to a final dose of 50 mg/day for 2 months. In 35 patients, the efficacy of Ep was evaluated by peripheral BP, proteinuria, and the transtubular K gradient (TTKG). Fifteen patients had additional analysis for central BP, plasma renin activity (PRA) and plasma aldosterone concentration (PAC), measured in the supine position, and 24-hour urine collection before and after receiving Ep. Results: Ep add-on therapy reduced the mean arterial pressure (p=0.0005) and central BP (p=0.009) independently to the baseline PAC. Ep induced PRA, but failed to show effects on PAC, TTKG, or albuminuria. Correlation analysis showed inverse relationships between the percent reduction in albuminuria and baseline PAC. Conclusions: Ep add-on therapy in patients taking renin-angiotensin system blockers is expected to reduce BP, even in patients with low PAC. In contrast, the anti-proteinuric action of Ep is dependent on baseline plasma aldosterone levels. TTKG is not appropriate for evaluating the efficacy of Ep.
Introduction
Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II type I receptor antagonists (ARBs) have been established as the first-line agents for patients with chronic kidney disease (CKD). 1, 2 Studies have shown that these agents reduce proteinuria and preserve the glomerular filtration rate (GFR). Angiotensin II regulates aldosterone production. Therefore, it has been considered that the blockade of angiotensin II action by ACEis or ARBs may also blunt aldosterone production. Based on this speculation, and the facts that ACEis or ARBs are more effective under salt restriction, consideration has been given to calcium (Ca) antagonists and thiazide diuretics as candidates for second-line agents because these agents possess natriuretic action. 3, 4 Little attention has been paid to the clinical effects of an aldosterone receptor antagonist (another natriuretic agent) add-on in patients who are already receiving an ACEi or ARB.
ACEi or ARB do reduce plasma aldosterone concentration (PAC) in the short term, but there are patients who present with re-elevated PAC during the course of ACEi or ARB treatment. [5] [6] [7] It has also become apparent that there are several aldosterone-independent pathways for mineralocorticoid receptor (MR) activation. [8] [9] [10] These findings have given impetus to investigating the effects of an antialdosterone agent add-on in patients who are already taking an ACEi or ARB. According to Navaneethan et al., 11 spironolactone, a classical aldosterone blocker, decreases blood pressure (BP) and has anti-proteinuric effects in patients with CKD undergoing therapy with renin-angiotensin system (RAS) inhibitors. However, these investigators also showed that the anti-proteinuric effects were highly variable among the patients studied. Eplerenone (Ep) has also been shown to have anti-proteinuric effects, but a high prevalence of non-responders were found in the same study. 12 Presently, it is not known what causes the differences between responders and non-responders, but Yoneda et al. have shown that subjects who developed higher aldosterone concentration (aldosterone breakthrough) 13 are more likely to develop proteinuria. Moranne et al. found that initial plasma potassium and aldosterone concentrations, as well as higher decreases in sodium intake, systolic BP (SBP), and estimated GFR (eGFR) from baseline to 1 year were factors that influence plasma aldosterone level. 14 The aim of the present study was to determine whether those parameters mentioned above, including initial plasma potassium and aldosterone concentration, higher decreases in sodium intake, SBP, and eGFR from baseline to 1 year, as well as the transtubular K gradient (TTKG) (an index of potassium secretion from the collecting ducts), can predict the clinical effects of Ep add-on therapy on BP and proteinuria in patients already taking ACEis or ARBs.
Materials and methods

Patients
Enrolled patients met the following inclusion criteria: (1) use of an ACEi or ARB due to hypertension or CKD; (2) absence of diabetic nephropathy; (3) eGFR >35 ml/min/1.73 m 2 ; (4) serum potassium level <4.8 mEq/l; (5) no history of receiving potassium adsorbent therapy; and (6) provision of informed consent to participate in the study.
The endpoint of the present study was BP. Serum sodium, potassium and creatinine were also obtained to assess the adverse effects of Ep administration. After the 2-month study period, patients who had successfully increased the dose of Ep to 50 mg/day for 1 month were used for analysis. The present study was conducted according to the principles of the Declaration of Helsinki and was approved by the local ethics committee of our institution. All patients provided informed, written consent prior to participation.
Study design and statistics
During the course of the study, patients were treated with a gradually increased dose of Ep, with an initial dose of 25 mg/day to a final dose of 50 mg/day for 2 months. This final dose was selected under the consideration of possible risk of hyperkalemia in subjects with CKD. Adverse side effects were assessed and recorded for all patients. There was a total of 35 study patients (Group A+B: male 19/female 16, age 56.0 [45.0-68.5]; Group A: male 12/female 8, age 59.5 [49.5-68.5], Group B: male 7/female 8, age 51.0 [43.5-68.5]). Group A and B subjects received same treatment but the obtained parameters were different. In both Group A and B subjects, the baseline peripheral BP (PBP), heart rate, and serum and spot urine sodium/potassium/osmolality/ creatinine were evaluated. After 2 months, the efficacy of Ep was evaluated by PBP, proteinuria, and TTKG in spot urine. Subjects with proteinuria >0.1 g/gCrtn were used to evaluate the anti-proteinuric action of Ep. In Group B subjects, in addition to the parameters obtained in Group A, measurement of estimated central BP (CBP) by HEM-9000AI (Omron, Kyoto, Japan), 15 blood sampling in the supine position and 24-hour urine collection were included to evaluate the clinical impact of Ep add-on therapy on CBP, plasma renin activity (PRA), PAC, TTKG 24hr and urinary albumin excretion. Among the 15 subjects in Group B, 14 subjects who excreted albumin >30 mg/day were used to evaluate the anti-proteinuric action of Ep. Serum creatinine was measured by an enzymatic method. The equation for Japanese eGFR:
was applied to calculate the eGFR. 16 Differences in laboratory findings between basal levels and the levels at 2 months were tested by the Wilcoxon rank sum test with continuity correction for correlated samples. The r 2 values given by correlation analysis of two factors were converted to p-values according to sample numbers. Continuous variables were expressed as mean ± standard deviation or median and interquartile ranges, as appropriate, and categorical variables were given as number and proportion. Statistical significance was set at p<0.05. Statistical analyses were performed using R, version 3.0.1 (The R Foundation for Statistical Computing, http://www.r-project.org/).
Results
Thirty-eight patients were enrolled in this study. During the 2-month study period, three patients were excluded from the protocol due to failure to increase the Ep dose to 50 mg/day or failure in maintaining continuous administration due to side effects, including general fatigue or abnormal serum creatinine elevation.
In the total number of patients (Group A+B), administration of the 50 mg/day dose of Ep significantly reduced PBP (SBP, diastolic BP [DBP], and mean arterial pressure [MAP]) in the sitting position (Table 1 and Figure 1 ). Heart rate, hemoglobin level, serum sodium, serum potassium, serum albumin, serum uric acid, blood urea nitrogen, serum creatinine, eGFR, urinary protein and TTKG spot were not affected by the administration of Ep (Table 1 and Figure 1 ). Among the parameters which have been reported to regulate plasma aldosterone level, 13, 14 baseline PAC was inversely correlated with baseline eGFR ( Figure  2) . No correlations were identified between baseline PAC and serum potassium, sodium intake, TTKG spot , TTKG 24hr . Administration of Ep reduced SBP, DBP, and MAP, but had no effect on proteinuria or TTKG spot . The values of the median and interquartile ranges are also shown in Table 1 .
or SBP. The administration of Ep reduced CBP, and increased PRA (Figure 3 ). Ep had no effects on PAC, TTKG 24hr , or urinary albumin excretion in the Group B patients (Figure 3 ). To further investigate the effects of Ep on BP and proteinuria, the relationships between the parameters before the administration of Ep and the percent changes in MAP, CBP, and albuminuria after the administration of Ep were tested by correlation analysis. The percent changes of MAP or CBP with Ep administration showed no relationships with serum potassium, PAC, percent change in salt intake, percent change in eGFR, TTKG spot , TTKG 24hr , or percent change in albuminuria (data not shown). Percent change in albuminuria showed no relationships with serum potassium, percent change in salt intake, or percent change in eGFR, TTKG spot , TTKG 24hr (data not shown), but rather, an inverse relationship was identified with PAC ( Figure 4) . This may represent the significant role of the direct or indirect action of plasma aldosterone on the occurrence or prognosis of proteinuria.
Discussion
The present study showed that the addition of an antialdosterone agent, eplerenone, in patients already taking ACEis or ARBs reduces PBP and CBP independently to the plasma aldosterone level. Aldosterone increases BP by promoting sodium retention in the kidneys and by direct action on the central nervous system and vessels. Aldosterone generates its biological actions by binding to a MR. Recent investigation has shown that MR activation is not entirely regulated by the aldosterone level. Fujita et al. showed an alternative pathway of MR activation by small GTPase Rac1. 9, 10 These investigators demonstrated that constitutive active Rac1 induces nuclear translocation of MR even in the absence of aldosterone. Therefore, the activators for Rac1 signaling may stimulate MR independently of the aldosterone level. MR can also be activated by glucocorticoids. The affinity of cortisol for MR is identical to the affinity of aldosterone, and the concentration of cortisol is 1000 times higher than aldosterone. 17 In general, cells that possess MR express 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2), which converts cortisol to inactive cortisone. 18, 19 However, vascular smooth muscle cells and distal tubule cells express marginal amounts of 11βHSD2. These cells activate MR by cortisol and increase BP by promoting vasoconstriction or sodium retention. This MR action can be blocked by Ep, and the BP is reduced independently of the PAC.
Buter et al. have demonstrated that the beneficial effects of ACEis are prominent under dietary salt restriction, but are limited under salt loading. 20 Therefore, the agents that have natriuretic actions, including diuretics and Ca antagonists, have been considered as the best additive antihypertensive agents to ACEis or ARBs, 3, 4 including for use in patients with CKD. Little attention has been paid to the clinical impact of add-on therapy for aldosterone receptor antagonists in patients who are already receiving ACEis or ARBs. The present study has shown a steady BP-lowering effect of Ep. As was discussed previously, the antihypertensive and natriuretic actions of anti-aldosterone agents can theoretically be expected even under a low aldosterone level. Therefore, we have concluded that Ep is a useful candidate as an additive anti-hypertensive agent for ACEis and ARBs.
Correlation analysis revealed that the subjects with higher basal PAC were more likely to experience reduced albuminuria with Ep. This finding is consistent with the concept that proteinuria is more prominent in patients who have had an aldosterone breakthrough. [5] [6] [7] The effect of Ep on proteinuria, which is dependent on the plasma aldosterone level, contrasts with the effect of Ep on BP, which is independent of the plasma aldosterone level. The precise mechanism of this differing action of Ep on BP and proteinuria is not known, but an explanation can be proposed by the expression of 11βHSD2 in glomeruli. Glomerular endothelial cells and podocytes have an established role in proteinuria. These cells have been shown to express 11βHSD2, 18 and MRs in these cells are activated only by aldosterone, because cortisol is inactivated in these cells.
We have concluded that TTKG is not a useful index to evaluate the efficacy of aldosterone receptor blockade. The present study showed no correlation between the TTKG and plasma aldosterone level, and, surprisingly, the administration of Ep failed to lower the TTKG. The TTKG is an index of potassium secretion in the collecting ducts. 21 In the collecting duct cells, aldosterone promotes potassium secretion by activating renal outer medullary potassium channel. Therefore, a higher plasma aldosterone level is expected to be correlated with a higher TTKG and a lower plasma potassium level. The present study failed to show any such relationship. A possible explanation is the activation of a compensatory pathway that promotes potassium secretion under aldosterone receptor blockade, which would include prostaglandins, nitric oxide, carbon monoxide and reduced oxidative stress. [22] [23] [24] [25] [26] The present study results provide some clues about the regulation of the plasma aldosterone level in subjects receiving ACEis or ARBs. In primary aldosteronism, elevation of the PAC is accompanied by a low potassium level. On the other hand, the present study found that the plasma potassium level is not lower in subjects with high aldosterone levels. This result indicates that the aldosterone level of these subjects is likely to be regulated not primarily, but secondarily by other factors. We have shown that there is an inverse correlation between PAC and eGFR. Besides the well-recognized regulation effect by angiotensin II, plasma potassium, endothelin and adrenocorticotropic hormone have also been shown to play important roles in the regulation of aldosterone production. 27, 28 The elevation of aldosterone under lower eGFR may play a physiological role in potassium homeostasis, because aldosterone can promote potassium secretion from the collecting ducts. This may compensate for the disturbed potassium excretion under reduced GFR. Further investigation is necessary to understand the regulation of aldosterone production under the administration of ACEis and ARBs.
In conclusion, Ep add-on therapy in patients who are receiving RAS blockers reduces PBP and CBP. The antihypertensive effect of Ep is independent of the plasma aldosterone level. In contrast, the anti-proteinuric action of Ep may be dependent upon the plasma aldosterone level. The TTKG is not an appropriate means for evaluating the efficacy of aldosterone receptor blockade.
